| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.5 | 0.6 |
| Gross profit | 0.0 | 0.3 |
| Profit before tax | -2.4 | -4.5 |
| Net income | -1.6 | -2.1 |
| EPS (diluted, $ a share) | $-0.05 | $-0.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -16.4% |
|---|---|
| Gross margin | 7.2% |
10-Q filed with the SEC, OTC: OSRH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
OSR Health, Inc.: key numbers
- Share price
- $0.1165Close, Nov 16
- Market cap
- $4.11M
- Shares outstanding
- 35.26MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from OSR Health, Inc.
All →OSR Health Other 8-K Filing
Shinhan Accounting Corporation resigned as OSR Health's independent auditor on November 6, 2026, citing overdue fees that created a potential independence threat. The company's previous financial reports included a going concern warning and identified material weaknesses in internal control over financial reporting. The Audit Committee has accepted the resignation and is currently seeking a successor accounting firm.
- Counterparty
- Shinhan Accounting Corporation
OSR Health Nasdaq/NYSE Compliance Notice
OSR Health received a written decision from the Nasdaq Hearings Panel on October 23, 2026, denying its request for continued listing and determining to delist the company's securities. The delisting follows the company's failure to regain compliance with the $1.00 minimum bid price requirement, and its securities will continue to be quoted on the over-the-counter market under the symbols OSRH and OSRHW.
- Counterparty
- The Nasdaq Stock Market LLC
OSR Health $15M Debt Financing with BCM Europe AG
OSR Health entered into an amendment to its license agreement with BCM Europe AG to add a convertible note option as an alternative settlement for a $15 million equity put option. The change was triggered by a Nasdaq delisting determination and allows the company to issue up to $15 million in convertible notes in four tranches with fixed conversion prices ranging from $2.00 to $5.00 per share.
- Value
- $15M
- Counterparty
- BCM Europe AG
OSR Health Leadership Change
Dr. Constance Hoefer resigned as Chief Scientific Officer of OSR Health, Inc., effective September 30, 2026. The company stated the departure was not due to any dispute or disagreement regarding operations, policies, or practices.